The US FDA ran hot and cold for sponsors this week. Here's your news in brief. Mylan NV is the latest to sponsor of a Neulasta (pegfilgrastim) biosimilar to strikeout at FDA, becoming the fourth company to receive a complete response letter (CRL) for a copycat candidate.
AcelRx Pharmaceuticals Inc. also ran into an agency stop sign with a CRL for its acute pain opioid Dsuvia...







